PAPERS

Advanced Technologies, Manufacturing, and Testing Solutions for Cell and Gene Therapy Innovators WuXi Advanced Therapies (WuXi ATU), the advanced therapies business unit of WuXi AppTec, is a Contract Testing, Development, and Manufacturing Organisation (CTDMO) that...

As gene therapies continue to offer huge hope for patients of hard-to-treat diseases, the challenges that they pose, from therapy design to manufacture and testing, demand clear and effective solutions. Gene therapies have the potential to provide a cure for...

Beginning with the end in mind: how early plasmid design and CDMO partnership can set you up for success in cell or gene therapy manufacturing Plasmids are important tools for building gene therapies, but substantial challenges exist for manufacturing a plasmid-based...

WuXi Advanced Therapies is the advanced therapies business unit of WuXi AppTec, with a globally integrated, full value chain operational model working to serve clients in the cell and gene therapy sectors. With four sites on three continents, WuXi Advanced Therapies has a...

The technology and infrastructure behind gene therapy treatments has hampered its route to market. But the future is bright for patients

WuXi Advanced Therapies (WuXi ATU), the advanced therapies business unit of WuXi AppTec, is a Contract Testing Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing and...

Lentiviral vectors (LVV) are commonly used as gene delivery tools for cell and gene therapies, notably chimeric antigen receptor (CAR) T cell therapies. Like other retroviruses, lentiviruses can convert their single-stranded RNA genome into double-stranded DNA when...

In the twenty years since creation of the first effective CAR-T cells, lentiviral vectors have become valuable tools for the development of ex vivo gene and cell therapies. Two ex vivo lentiviral gene therapy products have recently reached the market, one approved for...

Gene therapy is one of the most exciting fields of biopharma today, but plasmids pose serious challenges for innovation and drug development. WuXi’s acquisition of OXGENE means a fusion of expertise, helping to create an efficient means of developing plasmids on a large...

A new transfection-free helper system supports a high-yield manufacturing process for recombinant adeno-associated viruses (rAAV), raising the bar for producing safe, high-quality viral vectors at scale. To learn more about TESSA, evaluate it or discuss partnering to...